Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX trial in residual triple-negative breast cancer
ISRCTN47127434Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of olaparib, durvalumab and ceralasertib in triple-negative breast cancer (TNBC) and breast cancer (7 cohorts), sponsored by The Institute of Cancer Research. Primary endpoints: Ki67 proliferation change in cohorts B and C, Proliferation gene expression signature change in cohorts B and C and 5 more. Started Nov 2019; status: recruiting.
02
Drugs
olaparibdurvalumabceralasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ISRCTN47127434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47127434.